Skip to main content
SpringerLink
Log in

Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Treatment options for patients who progressed to castration-resistant prostate cancer (CRPC) are very limited. The purpose of this study was to assess the efficacy of estramustine phosphate (EMP) in patients with CRPC, grouped according to the risk classification advocated by Armstrong et al. and to identify candidates for EMP treatment. Between March 2003 and July 2010, 82 patients with CRPC were treated with 280 or 560 mg EMP per os daily until disease progression or occurrence of unacceptable adverse events. Prostate-specific antigen (PSA) response and overall survival were evaluated according to risk classification. 52 (67%) patients achieved PSA decline. Rates of PSA decline in the good-, intermediate-, and poor-risk groups were 77, 71, and 25%, respectively, significantly higher in the good- and intermediate-risk groups than the poor-risk group (p = 0.03). The median overall survival times in good-, intermediate-, and poor-risk groups were 21, 19, and 9 months, respectively (p = 0.005 for good vs intermediate, p = 0.001 for intermediate vs poor). When the intermediate-risk group was divided into two subgroups by PSA doubling time (PSADT), men with PSADT ≥ 2 months achieved higher PSA response rate (88%) and longer survival (22 months) than those with PSADT < 2 months (53%, 15 months). Patients with good-risk or intermediate-risk with PSA doubling time ≥2 months achieved favourable PSA response and survival and may benefit from chemotherapy with EMP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Smaletz O, Scher HI, Small EJ, Verval DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972–8.

    Article  PubMed  Google Scholar 

  2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med. 2004;351:1502–12.

    Article  CAS  Google Scholar 

  3. Petrylak DP, Tangen CM, Hussain MH, Lura PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

    Article  PubMed  CAS  Google Scholar 

  4. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone ormitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242–5.

    Article  PubMed  CAS  Google Scholar 

  5. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80.

    Article  PubMed  Google Scholar 

  6. Mohler J, Bahnson RR, Boston B, Busby JE, D’amico A, Easthan JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Cancer Netw. 2010;8:162–200.

    CAS  Google Scholar 

  7. Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S, et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol. 2008;38:365–72.

    Article  PubMed  CAS  Google Scholar 

  8. Shelley M, Harrison C, Coles B, Staffurth J, Wilt T, Masson M. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev. 2006;. doi:10.1002/14651858.

    Google Scholar 

  9. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010;46:517–25.

    Article  PubMed  CAS  Google Scholar 

  10. Oudard S, Banu E, Scotte F, Banu A, Medioni J, Beuzeboc P, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol. 2007;18:1828–33.

    Article  PubMed  CAS  Google Scholar 

  11. Iverson P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. J Urol. 1997;157:929–34.

    Article  Google Scholar 

  12. Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int. 2005;75:43–9.

    Article  PubMed  CAS  Google Scholar 

  13. Benson RC, Wear JB, Gill GM. Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate. J Urol. 1979;121:452–4.

    PubMed  CAS  Google Scholar 

  14. Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauv M, Sylvester R. Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, Genitourinary Group prospective randomized phase III study (30865). J Urol. 1993;150:1840–4.

    PubMed  CAS  Google Scholar 

  15. Elomaa I, Kellokumpu-Lehtinen P, Ranniko S, Alfthan O. Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments. Eur Urol. 1991;19:12–5.

    PubMed  CAS  Google Scholar 

  16. Johansson JE, Andersson SO, Holmberg L. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomized study. Br J Urol. 1991;68:67–73.

    Article  PubMed  CAS  Google Scholar 

  17. Maier U, Hienert G, Simak R. Estramustine phosphate in secondary hormone-resistant carcinoma of the prostate. Eur Urol. 1990;17:216–8.

    PubMed  CAS  Google Scholar 

  18. Soloway MS, deKerinion JB, Gibbons RP, Johnson DE, Loening SA, Pontes JE, et al. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone refractory, previously irradiated carcinoma of the prostate. J Urol. 1981;125:664–7.

    PubMed  CAS  Google Scholar 

  19. Albrecht W, Poppel HV, Horenblas S, Mickisch G, Horwich A, Serreta V, et al. Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer. 2004;90:100–5.

    Article  PubMed  CAS  Google Scholar 

  20. Serretta V, Altieri V, Morgia G, Siragusa A, De Grande G, Naopoli M, et al. Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital. Urol Int. 2009;83:452–7.

    Article  PubMed  CAS  Google Scholar 

  21. Perry CM, Mctavish D. Estramusutine phosphate sodium: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drug Aging. 1995;7:49–74.

    Article  CAS  Google Scholar 

  22. Hamberg P, Verhagen PCMS, de Wit R. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer. 2008;44:1193–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, School of Medicine, University of Occupational and Environmental Health, 1-1, Iseigaoka, Yahata-nishi-ku, Kitakyushu, 807-8555, Japan

    Akinori Minato, Naohiro Fujimoto & Tetsuro Matsumoto

  2. Department of Public Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

    Tatsuhiko Kubo

  3. Department of Urology, Shin Yukuhashi Hospital, Yukuhashi, Japan

    Shuji Harada

  4. Department of Urology, Moji Medical Center, Kitakyushu, Japan

    Soichiro Akasaka

Authors
  1. Akinori Minato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naohiro Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatsuhiko Kubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shuji Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soichiro Akasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tetsuro Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naohiro Fujimoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minato, A., Fujimoto, N., Kubo, T. et al. Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer. Med Oncol 29, 2895–2900 (2012). https://doi.org/10.1007/s12032-012-0178-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0178-z

Keywords

Search

Navigation